Published in BMC Syst Biol on January 11, 2012
Proteogenomic convergence for understanding cancer pathways and networks. Clin Proteomics (2014) 0.83
Pathway mapping and development of disease-specific biomarkers: protein-based network biomarkers. J Cell Mol Med (2015) 0.80
Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancer. PLoS One (2013) 0.79
MicroRNA regulation of molecular pathways as a generic mechanism and as a core disease phenotype. Oncotarget (2015) 0.79
The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells. J Ovarian Res (2014) 0.78
Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma. Int Sch Res Notices (2014) 0.77
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet (1998) 21.52
PID: the Pathway Interaction Database. Nucleic Acids Res (2008) 12.92
A global test for groups of genes: testing association with a clinical outcome. Bioinformatics (2004) 10.82
Role of platelet-derived growth factors in physiology and medicine. Genes Dev (2008) 8.89
High-throughput DNA methylation profiling using universal bead arrays. Genome Res (2006) 8.05
The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell (1988) 7.76
Analysis of gene expression data using BRB-ArrayTools. Cancer Inform (2007) 6.09
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene (2002) 5.96
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
CpG methylation, chromatin structure and gene silencing-a three-way connection. EMBO J (1998) 4.61
Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell (1997) 4.26
Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature (2008) 4.24
Resolving the resolution of array CGH. Genomics (2007) 3.66
Inferring pathway activity toward precise disease classification. PLoS Comput Biol (2008) 3.48
Structure and chromosomal localization of the functional intronless human JUN protooncogene. Proc Natl Acad Sci U S A (1988) 2.51
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol (1994) 2.50
Identification of key processes underlying cancer phenotypes using biologic pathway analysis. PLoS One (2007) 2.18
Targeting Stat3 in cancer therapy. Anticancer Drugs (2005) 2.13
STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene (2004) 1.96
Role of DNA 5-methylcytosine transferase in cell transformation by fos. Science (1999) 1.83
miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene (2010) 1.82
High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res (2007) 1.81
Targeted disruption of the c-fos gene demonstrates c-fos-dependent and -independent pathways for gene expression stimulated by growth factors or oncogenes. EMBO J (1994) 1.61
Jak family of kinases in cancer. Cancer Metastasis Rev (2003) 1.52
Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS One (2010) 1.50
Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta (2010) 1.42
Gene silencing. Methylation meets acetylation. Nature (1998) 1.41
C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer (2000) 1.37
High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC Med Genomics (2009) 1.33
Gene Set Expression Comparison kit for BRB-ArrayTools. Bioinformatics (2007) 1.28
Molecular classification of solid tumours: towards pathway-driven therapeutics. Br J Cancer (2009) 1.23
Protein networks markedly improve prediction of subcellular localization in multiple eukaryotic species. Nucleic Acids Res (2008) 1.22
Effects of sample size on robustness and prediction accuracy of a prognostic gene signature. BMC Bioinformatics (2009) 1.18
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res (2009) 1.16
Ovarian cancer. Survival and treatment differences by age. Cancer (1993) 1.15
Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene (1989) 1.11
Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta. J Biol Chem (2002) 1.11
Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Arch Pathol Lab Med (2003) 1.08
C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer (2008) 1.08
Can survival prediction be improved by merging gene expression data sets? PLoS One (2009) 1.04
DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol (2001) 1.03
Hunting for the 5th base: Techniques for analyzing DNA methylation. Biochim Biophys Acta (2009) 1.03
Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts. Mol Cancer Ther (2010) 1.02
The PathOlogist: an automated tool for pathway-centric analysis. BMC Bioinformatics (2011) 0.99
Detecting cancer gene networks characterized by recurrent genomic alterations in a population. PLoS One (2011) 0.94
Targeting angiogenesis in ovarian cancer. Cancer Treat Rev (2011) 0.93
Integrative analysis of a cancer somatic mutome. Mol Cancer (2007) 0.92
Omnibus permutation tests of the association of an ensemble of genetic markers with disease in case-control studies. Genet Epidemiol (2006) 0.91
Superposition of transcriptional behaviors determines gene state. PLoS One (2008) 0.91
Hunting for robust gene signature from cancer profiling data: sources of variability, different interpretations, and recent methodological developments. Cancer Lett (2010) 0.89
Activation and inhibition of the AP-1 complex in human breast cancer cells. Mol Carcinog (1996) 0.89
Systems biology: opening new avenues in clinical research. Nephrol Dial Transplant (2010) 0.84
Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines. Oncol Rep (2009) 0.83
What does systems biology mean for biomarker discovery? Expert Opin Med Diagn (2010) 0.81
Rep-Seq: uncovering the immunological repertoire through next-generation sequencing. Immunology (2012) 1.99
Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology (2010) 1.97
Gene expression and network-based analysis reveals a novel role for hsa-miR-9 and drug control over the p38 network in glioblastoma multiforme progression. Genome Med (2011) 1.54
IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol (2013) 1.50
Gene expression profile of empirically delineated classes of unexplained chronic fatigue. Pharmacogenomics (2006) 1.10
Altered immune pathway activity under exercise challenge in Gulf War Illness: an exploratory analysis. Brain Behav Immun (2012) 1.02
The PathOlogist: an automated tool for pathway-centric analysis. BMC Bioinformatics (2011) 0.99
The whole-organism heavy chain B cell repertoire from Zebrafish self-organizes into distinct network features. BMC Syst Biol (2011) 0.90
Immune-induced evolutionary selection focused on a single reading frame in overlapping hepatitis B virus proteins. J Virol (2011) 0.88
RBM38 is a direct transcriptional target of E2F1 that limits E2F1-induced proliferation. Mol Cancer Res (2012) 0.84
MicroRNA-gene association as a prognostic biomarker in cancer exposes disease mechanisms. PLoS Comput Biol (2013) 0.83
Reactive animation: from piecemeal experimentation to reactive biological systems. Autoimmunity (2011) 0.81
Spatial regulation dominates gene function in the ganglia chain. Bioinformatics (2013) 0.81
Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma. Cell Commun Signal (2015) 0.79
SENP5 mediates breast cancer invasion via a TGFβRI SUMOylation cascade. Oncotarget (2014) 0.78
Systems analysis utilising pathway interactions identifies sonic hedgehog pathway as a primary biomarker and oncogenic target in hepatocellular carcinoma. IET Syst Biol (2013) 0.77
Experimental Support for the Ecoimmunity Theory: Distinct Phenotypes of Nonlymphocytic Cells in SCID and Wild-Type Mice. Cell Transplant (2016) 0.75